JP2010522152A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522152A5 JP2010522152A5 JP2009554083A JP2009554083A JP2010522152A5 JP 2010522152 A5 JP2010522152 A5 JP 2010522152A5 JP 2009554083 A JP2009554083 A JP 2009554083A JP 2009554083 A JP2009554083 A JP 2009554083A JP 2010522152 A5 JP2010522152 A5 JP 2010522152A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- bone
- compound according
- ring
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 14
- 206010061218 Inflammation Diseases 0.000 claims 12
- 230000004054 inflammatory process Effects 0.000 claims 12
- 206010065687 Bone loss Diseases 0.000 claims 10
- 230000004913 activation Effects 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 125000001931 aliphatic group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 208000020084 Bone disease Diseases 0.000 claims 6
- 206010023203 Joint destruction Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 210000000987 immune system Anatomy 0.000 claims 6
- 210000002997 osteoclast Anatomy 0.000 claims 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 208000006386 Bone Resorption Diseases 0.000 claims 4
- 108010002352 Interleukin-1 Proteins 0.000 claims 4
- 102000000589 Interleukin-1 Human genes 0.000 claims 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims 4
- 208000001132 Osteoporosis Diseases 0.000 claims 4
- 208000027067 Paget disease of bone Diseases 0.000 claims 4
- 102000014128 RANK Ligand Human genes 0.000 claims 4
- 108010025832 RANK Ligand Proteins 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 208000016738 bone Paget disease Diseases 0.000 claims 4
- 230000024279 bone resorption Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000018084 Bone neoplasm Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000007943 implant Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000007774 longterm Effects 0.000 claims 2
- 239000004579 marble Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 claims 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 0 *N([Al]I*)S([Al][Al]I)(=O)=O Chemical compound *N([Al]I*)S([Al][Al]I)(=O)=O 0.000 description 12
- SPTJCYWEGIYIJX-UCNYIJHQSA-N C/C=C(/C1C=CC(S(/N=C2\C=CC=C(CCCO)C2)(=O)=O)=CC=C1)\C(\F)=C/C(F)=C Chemical compound C/C=C(/C1C=CC(S(/N=C2\C=CC=C(CCCO)C2)(=O)=O)=CC=C1)\C(\F)=C/C(F)=C SPTJCYWEGIYIJX-UCNYIJHQSA-N 0.000 description 1
- IRADXTURDJBIPE-UHFFFAOYSA-N C=C(C1)C(c(ccc(Cl)c2)c2Cl)=CC=C1S(Nc1cc(CCO)ccc1)(=O)=[U] Chemical compound C=C(C1)C(c(ccc(Cl)c2)c2Cl)=CC=C1S(Nc1cc(CCO)ccc1)(=O)=[U] IRADXTURDJBIPE-UHFFFAOYSA-N 0.000 description 1
- YUFKSFFAHGRLQJ-UHFFFAOYSA-N Cc(cc1)ccc1-c(cc1)ccc1S(Nc1cccc(CO)c1)(=N)=O Chemical compound Cc(cc1)ccc1-c(cc1)ccc1S(Nc1cccc(CO)c1)(=N)=O YUFKSFFAHGRLQJ-UHFFFAOYSA-N 0.000 description 1
- YOGYLSSOGBIQMI-UHFFFAOYSA-N OCc(cc1)c(CO)cc1NS(c(cc1)ccc1-c(ccc(Cl)c1)c1Cl)(=O)=O Chemical compound OCc(cc1)c(CO)cc1NS(c(cc1)ccc1-c(ccc(Cl)c1)c1Cl)(=O)=O YOGYLSSOGBIQMI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0705400.0A GB0705400D0 (en) | 2007-03-21 | 2007-03-21 | Therapeutic compounds andm their use |
| GB0705400.0 | 2007-03-21 | ||
| PCT/GB2008/000989 WO2008114022A1 (en) | 2007-03-21 | 2008-03-20 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010522152A JP2010522152A (ja) | 2010-07-01 |
| JP2010522152A5 true JP2010522152A5 (enExample) | 2011-05-06 |
| JP5450105B2 JP5450105B2 (ja) | 2014-03-26 |
Family
ID=38024559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554083A Active JP5450105B2 (ja) | 2007-03-21 | 2008-03-20 | ビフェニル−４−イル−スルホン酸アリールアミド及びその治療剤としての使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8524778B2 (enExample) |
| EP (1) | EP2137141B1 (enExample) |
| JP (1) | JP5450105B2 (enExample) |
| CA (1) | CA2681320C (enExample) |
| DK (1) | DK2137141T3 (enExample) |
| ES (1) | ES2561163T3 (enExample) |
| GB (1) | GB0705400D0 (enExample) |
| HR (1) | HRP20160183T1 (enExample) |
| HU (1) | HUE028656T2 (enExample) |
| SI (1) | SI2137141T1 (enExample) |
| WO (1) | WO2008114022A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817207D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB0817208D0 (en) * | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| US9233946B2 (en) | 2010-09-17 | 2016-01-12 | Kancera Ab | Sulfonamide compounds |
| US9422224B2 (en) | 2011-06-13 | 2016-08-23 | Ergon Pharmaceuticals Llc | Methods of treatment using a BCAT1 inhibitor |
| US10941109B2 (en) | 2011-06-13 | 2021-03-09 | Ergon Pharmaceuticals Llc | Compositions and methods of treatment using a BCAT1 inhibitor |
| WO2013055793A1 (en) | 2011-10-12 | 2013-04-18 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
| CN104168958B (zh) * | 2011-12-22 | 2017-12-01 | 坎塞拉有限公司 | 可用于治疗炎症和癌症的二芳基磺酰胺 |
| HK1211019A1 (en) * | 2012-12-10 | 2016-05-13 | F. Hoffmann-La Roche Ag | Benzyl sulfonamide derivatives as rorc modulators |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| EP3046561B1 (en) | 2013-09-20 | 2023-02-22 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Compounds for treating prostate cancer |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| LT3262028T (lt) * | 2014-12-17 | 2022-01-10 | Pimco 2664 Limited | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamido ir n-(-4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamido junginiai ir jų terapinis panaudojimas |
| US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| JP7108638B2 (ja) | 2017-02-07 | 2022-07-28 | ライフストーン・アーエス | 無菌性弛みによるインプラント関連のインプラント再置換リスクの診断のためのバイオマーカー |
| WO2020097408A1 (en) * | 2018-11-09 | 2020-05-14 | Nimbus Artemis, Inc. | Acly inhibitors and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB597810A (en) | 1943-04-12 | 1948-02-04 | Gen Printing Ink Corp | Improvements in or relating to derivatives of diphenyl |
| DE1046220B (de) | 1956-04-21 | 1958-12-11 | Bayer Ag | Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen |
| US4119784A (en) | 1977-07-01 | 1978-10-10 | American Cyanamid Company | Anionic substituted sulfonamido biphenyls |
| GB2001307A (en) * | 1977-07-01 | 1979-01-31 | American Cyanamid Co | Sulphonamide blood complement inhibitors |
| DE3000519A1 (de) | 1979-02-01 | 1980-08-14 | Byk Gulden Lomberg Chem Fab | Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel |
| DE3535167A1 (de) | 1985-10-02 | 1987-04-09 | Boehringer Mannheim Gmbh | Neue sulfonyl-phenyl(alkyl)amine, verfahren zu ihrer herstellung sowie arzneimittel |
| IL118325A0 (en) | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
| CZ132798A3 (cs) | 1995-10-30 | 1999-02-17 | Smithkline Beecham Corporation | Inhibitory proteázy |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| EP0888344A1 (en) | 1996-03-15 | 1999-01-07 | The Du Pont Merck Pharmaceutical Company | Spirocycle integrin inhibitors |
| WO1998003166A1 (en) | 1996-07-22 | 1998-01-29 | Monsanto Company | Thiol sulfonamide metalloprotease inhibitors |
| HUP0000641A3 (en) * | 1996-10-16 | 2001-02-28 | American Cyanamid Company Madi | Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them |
| WO1998023608A1 (en) | 1996-11-27 | 1998-06-04 | Dupont Pharmaceuticals Company | Novel integrin receptor antagonists |
| WO1998043962A1 (en) | 1997-03-28 | 1998-10-08 | Du Pont Pharmaceuticals Company | Heterocyclic integrin inhibitor prodrugs |
| AU734302B2 (en) | 1997-05-08 | 2001-06-07 | Smithkline Beecham Corporation | Protease inhibitors |
| DE19719621A1 (de) | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| PT877019E (pt) | 1997-05-09 | 2002-05-31 | Hoechst Ag | Acidos diaminocarboxilicos substituidos |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| JP2002501054A (ja) | 1998-01-23 | 2002-01-15 | アヴェンティス ファルマ ドイチェラント ゲーエムベーハー | 骨吸収の阻害剤として及び細胞接着の阻害剤としての新規のスルホンアミド誘導体 |
| EP1053226A1 (en) | 1998-02-04 | 2000-11-22 | Novartis AG | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| JPH11246527A (ja) | 1998-03-02 | 1999-09-14 | Shionogi & Co Ltd | Ｍｍｐ−８阻害剤 |
| EP0960882A1 (en) | 1998-05-19 | 1999-12-01 | Hoechst Marion Roussel Deutschland GmbH | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists |
| CN1418210A (zh) | 2000-03-21 | 2003-05-14 | 宝洁公司 | 含有碳环侧链的n－取代金属蛋白酶抑制剂 |
| WO2001090077A1 (en) | 2000-05-19 | 2001-11-29 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| AU2002228316A1 (en) | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| JPWO2002074298A1 (ja) | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| US6849635B2 (en) * | 2001-05-07 | 2005-02-01 | Smithkline Beecham Corporation | Sulfonamides |
| NZ531153A (en) | 2001-08-09 | 2005-10-28 | Ono Pharmaceutical Co | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| GB0126157D0 (en) | 2001-10-31 | 2002-01-02 | Univ Aberdeen | Therapeutic compounds |
| TW200305396A (en) | 2002-03-27 | 2003-11-01 | Shionogi & Co | Cartilage extracellular matrix degradation |
| MXPA05002571A (es) | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| DE10251170A1 (de) * | 2002-10-31 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004073619A2 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Ccr8 antagonists |
| ES2298753T3 (es) * | 2003-05-07 | 2008-05-16 | The University Court Of The University Of Aberdeen | Cetonas y cetonas reducidas como agentes terapeuticos para el tratamiento de enfermedades oseas. |
| JPWO2004106290A1 (ja) | 2003-05-14 | 2006-07-20 | キッセイ薬品工業株式会社 | アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| BRPI0417687A (pt) | 2003-12-19 | 2007-04-03 | Pfizer | derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade |
| EP1723132A1 (en) * | 2004-02-12 | 2006-11-22 | Asterand Uk Limited | Ep2 receptor agonists |
| GB0405193D0 (en) | 2004-03-08 | 2004-04-21 | Medical Res Council | Compounds |
| US20080255240A1 (en) * | 2004-05-05 | 2008-10-16 | Novo Nordisk A/S | Sulfonamide Derivatives |
| GB0412553D0 (en) | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| WO2005123089A2 (en) * | 2004-06-10 | 2005-12-29 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| EP1659113A1 (en) | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| EA200702498A1 (ru) | 2005-06-16 | 2008-06-30 | Пфайзер Инк. | N-(пиридин-2-ил)сульфонамидные производные |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| TW200720261A (en) * | 2005-08-31 | 2007-06-01 | Sankyo Co | Phenylene derivatives |
| EA019879B1 (ru) | 2005-12-29 | 2014-07-30 | Лексикон Фармасьютикалз, Инк. | Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные |
| US7560597B2 (en) * | 2007-03-08 | 2009-07-14 | The University Court Of The University Of Aberdeen | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
-
2007
- 2007-03-21 GB GBGB0705400.0A patent/GB0705400D0/en not_active Ceased
-
2008
- 2008-03-20 WO PCT/GB2008/000989 patent/WO2008114022A1/en not_active Ceased
- 2008-03-20 HR HRP20160183T patent/HRP20160183T1/hr unknown
- 2008-03-20 CA CA2681320A patent/CA2681320C/en active Active
- 2008-03-20 US US12/531,732 patent/US8524778B2/en active Active
- 2008-03-20 EP EP08718826.4A patent/EP2137141B1/en active Active
- 2008-03-20 SI SI200831582T patent/SI2137141T1/sl unknown
- 2008-03-20 DK DK08718826.4T patent/DK2137141T3/en active
- 2008-03-20 ES ES08718826.4T patent/ES2561163T3/es active Active
- 2008-03-20 HU HUE08718826A patent/HUE028656T2/en unknown
- 2008-03-20 JP JP2009554083A patent/JP5450105B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3880041B2 (ja) | ６−メルカプト−シクロデキストリン誘導体：薬物誘導神経筋遮断回復薬 | |
| HRP20160183T1 (hr) | Arilamidi bifenil-4-il-sulfonske kiseline i njihova uporaba kao terapeutskih sredstava | |
| TW199896B (enExample) | ||
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| JP2008545652A5 (enExample) | ||
| JP2007501281A5 (enExample) | ||
| JP2020510054A5 (enExample) | ||
| JP2003506491A5 (enExample) | ||
| JP2701952B2 (ja) | Ｎ‐複素環プロピリデン‐１，１‐ビスホスホン酸、その製法および薬剤組成物 | |
| JPH0257049B2 (enExample) | ||
| JP2012502965A5 (enExample) | ||
| JPH07507317A (ja) | 異常なカルシウムおよびホスフェート代謝を治療するためのチオ置換窒素含有複素環式ホスホネート化合物 | |
| AU2003228593B2 (en) | Pharmaceutical composition comprising an alpha-ketoalkanoic acid ester or -amine and lactic acid or a lactic acid salt | |
| ES2533007T3 (es) | Compuesto de benzoacepina soluble en agua y su composición farmacéutica | |
| JP2011508757A (ja) | 骨組織を標的としたベクターとしてのヒドロキシ‐ビスホスホン酸誘導体 | |
| JP2025512877A5 (enExample) | ||
| JP2002531441A5 (enExample) | ||
| FR2973378A1 (fr) | Derives d'acide hydroxybisphosphonique bifonctionnels | |
| ES2945062T3 (es) | Derivados de ácido barbitúrico novedosos, su preparación y uso de los mismos como inhibidores de la transmigración de leucocitos y para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias y cáncer | |
| JP2021504302A5 (enExample) | ||
| JPWO2019031470A1 (ja) | 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| JP3883137B2 (ja) | ピリジルビスホスホン酸エステルよりなる治療用活性薬剤 | |
| JPH07507315A (ja) | カルシウムおよびホスフェート代謝異常治療用含硫ホスホネート化合物 | |
| RU2003122189A (ru) | Сульфамидотиенопиримидины | |
| JP2023553989A5 (enExample) |